SINOPHARM (01099): China National Accord Medicines Corporation's net profit attributable to shareholders in the first half of the year was 606 million yuan, a year-on-year decrease of 8.97%.

SINOPHARM (01099) announced that China National Accord Medicines Corporation reported its half-year performance for 2026, achieving an operating revenue of RMB 36.266 billion, a year-on-year decrease of 1.44%; operating profit of RMB 834 million, a year-on-year decrease of 9.94%; total profit of RMB 827 million, a year-on-year decrease of 9.88%; and net profit attributable to shareholders of the listed company of RMB 606 million, a year-on-year decrease of 8.97%. Correspondingly, the basic earnings per share saw a year-on-year decrease of 9.17%. Revenue and profit have shown a trend of narrowing decline compared to the first quarter, while the weighted average return on net assets decreased by 0.49 percentage points year-on-year. In the first half of 2026, the distribution segment achieved an operating revenue of RMB 26.539 billion, a year-on-year decrease of 0.91%; net profit of RMB 460 million, a year-on-year decrease of 4.56%. Despite the ongoing pressure from deepening industry policies affecting short-term operations, China National Accord Medicines Corporation has demonstrated good operational resilience through increasing volume, adjusting structure, and refined management, with the rate of decline in revenue and profit continuing to narrow. The retail segment (i.e., "GuoDa Pharmacy") achieved an operating revenue of RMB 10.227 billion, a year-on-year decrease of 2.40%, with the decline narrowing; it realized a net profit of RMB 13 million, a year-on-year decrease of 19.74%. Affected by industry policy adjustments and intensified market competition, GuoDa Pharmacy's sales revenue experienced a slight decline; combined with changes in sales structure, a lower proportion of high-margin products sold led to a reduction in gross margin and, consequently, profit decline.